Q3 EPS Estimates for Gilead Sciences Cut by Zacks Research

Gilead Sciences, Inc. (NASDAQ:GILD) – Zacks Research cut their Q3 2026 EPS estimates for Gilead Sciences in a research note issued to investors on Tuesday, February 25th. Zacks Research analyst E. Bagri now forecasts that the biopharmaceutical company will post earnings per share of $2.20 for the quarter, down from their prior forecast of $2.21. The consensus estimate for Gilead Sciences’ current full-year earnings is $7.95 per share.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%.

Several other analysts have also recently commented on GILD. The Goldman Sachs Group raised their target price on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 12th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. DZ Bank raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 target price for the company in a report on Thursday, February 13th. Royal Bank of Canada upped their price target on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a research note on Wednesday, February 12th. Finally, Wells Fargo & Company increased their target price on shares of Gilead Sciences from $105.00 to $120.00 and gave the company an “overweight” rating in a report on Wednesday, February 12th. Eleven investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $102.08.

Gilead Sciences Stock Up 2.1 %

Gilead Sciences stock opened at $114.31 on Friday. Gilead Sciences has a twelve month low of $62.07 and a twelve month high of $114.77. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The stock has a 50 day moving average of $97.42 and a two-hundred day moving average of $89.94. The stock has a market capitalization of $142.46 billion, a price-to-earnings ratio of 308.95, a PEG ratio of 0.71 and a beta of 0.18.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. HHM Wealth Advisors LLC raised its holdings in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares during the period. Valued Wealth Advisors LLC raised its holdings in Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 161 shares during the period. YANKCOM Partnership acquired a new position in Gilead Sciences during the fourth quarter valued at approximately $28,000. Decker Retirement Planning Inc. purchased a new stake in Gilead Sciences during the fourth quarter worth approximately $29,000. Finally, Crews Bank & Trust purchased a new stake in Gilead Sciences during the fourth quarter worth approximately $31,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the transaction, the chief financial officer now owns 129,873 shares of the company’s stock, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders have sold 293,356 shares of company stock valued at $29,166,240. Insiders own 0.16% of the company’s stock.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be given a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 2.76%. Gilead Sciences’s dividend payout ratio is 854.05%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.